BR112012015677A2 - Compostos farmacêuticos. - Google Patents

Compostos farmacêuticos.

Info

Publication number
BR112012015677A2
BR112012015677A2 BRBR112012015677-2A BR112012015677A BR112012015677A2 BR 112012015677 A2 BR112012015677 A2 BR 112012015677A2 BR 112012015677 A BR112012015677 A BR 112012015677A BR 112012015677 A2 BR112012015677 A2 BR 112012015677A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compounds
compounds
pharmaceutical
methods
well
Prior art date
Application number
BRBR112012015677-2A
Other languages
English (en)
Inventor
Lixin Zhang
Graham Peter Trevitt
Hughes Miel
Frank Burkamp
Timothy Harrison
Andrew John Wilkinson
Charles-Henry Fabritius
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of BR112012015677A2 publication Critical patent/BR112012015677A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Compostos farmacêuticos. A presente invenção se refere a uma série de compostos com atividade específica como inibidores da serino-treonino-quinase akt. São também proporcionadas composições farmacêuticas compreendendo os mesmos, bem como métodos para o tratamento do câncer.
BRBR112012015677-2A 2009-12-23 2010-12-23 Compostos farmacêuticos. BR112012015677A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
PCT/GB2010/002329 WO2011077098A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
BR112012015677A2 true BR112012015677A2 (pt) 2015-06-30

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
BRBR112012015677-2A BR112012015677A2 (pt) 2009-12-23 2010-12-23 Compostos farmacêuticos.

Country Status (22)

Country Link
US (1) US9221838B2 (pt)
EP (1) EP2516435B8 (pt)
JP (1) JP5923043B2 (pt)
KR (1) KR20140015157A (pt)
CN (1) CN102791708B (pt)
AU (1) AU2010334591C1 (pt)
BR (1) BR112012015677A2 (pt)
CA (1) CA2783340C (pt)
CY (1) CY1115686T1 (pt)
DK (1) DK2516435T3 (pt)
ES (1) ES2503794T3 (pt)
GB (1) GB0922589D0 (pt)
HK (1) HK1171013A1 (pt)
IL (1) IL220153A (pt)
MX (1) MX2012007274A (pt)
NZ (1) NZ600453A (pt)
PL (1) PL2516435T3 (pt)
PT (1) PT2516435E (pt)
RU (1) RU2579513C2 (pt)
SG (1) SG181517A1 (pt)
SI (1) SI2516435T1 (pt)
WO (1) WO2011077098A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
AU2015370911B2 (en) * 2014-12-23 2020-07-09 Bergenbio Asa Inhibitors of Akt kinase
US10323044B2 (en) * 2015-02-27 2019-06-18 Taiho Pharmaceutical Co., Ltd. Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
WO2018031407A1 (en) * 2016-08-07 2018-02-15 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pt346 pdk1
CN111132972A (zh) * 2017-06-22 2020-05-08 克拉德夫制药有限公司 人sting的小分子调节剂
IL305085A (en) 2017-09-07 2023-10-01 Univ Res Inst Inc Augusta A specific AKT3 activator and its uses
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0790997T3 (da) * 1994-11-14 2000-08-21 Warner Lambert Co 6-Aryl-pyrido[2,3-d]pyrimidiner og napthyridiner til hæmning af protein-tyrosin-kinase-fremkaldt celleproliferation
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
PT1898903E (pt) * 2005-06-10 2013-06-28 Merck Sharp & Dohme Inibidores da atividade de akt
CA2656507C (en) * 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
CA2670767A1 (en) 2006-12-06 2008-06-12 Merck & Co., Inc. Inhibitors of akt activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
MX2010013224A (es) 2008-06-03 2010-12-21 Merck Sharp & Dohme Inhibidores de la actividad de la serina/treonina cinasa.
CA2726317A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Also Published As

Publication number Publication date
HK1171013A1 (en) 2013-03-15
GB0922589D0 (en) 2010-02-10
CA2783340C (en) 2015-11-24
SI2516435T1 (sl) 2014-12-31
US9221838B2 (en) 2015-12-29
CY1115686T1 (el) 2017-01-25
CN102791708B (zh) 2016-03-02
WO2011077098A1 (en) 2011-06-30
SG181517A1 (en) 2012-07-30
AU2010334591C1 (en) 2014-07-31
EP2516435A1 (en) 2012-10-31
NZ600453A (en) 2013-10-25
AU2010334591A1 (en) 2012-06-21
RU2579513C2 (ru) 2016-04-10
MX2012007274A (es) 2012-10-03
KR20140015157A (ko) 2014-02-06
DK2516435T3 (da) 2014-10-13
CN102791708A (zh) 2012-11-21
WO2011077098A9 (en) 2012-04-19
IL220153A0 (en) 2012-07-31
IL220153A (en) 2015-05-31
EP2516435B8 (en) 2014-10-15
ES2503794T3 (es) 2014-10-07
JP2013515710A (ja) 2013-05-09
PL2516435T3 (pl) 2015-01-30
JP5923043B2 (ja) 2016-05-24
PT2516435E (pt) 2014-11-13
RU2012131115A (ru) 2014-01-27
CA2783340A1 (en) 2011-06-30
AU2010334591B2 (en) 2014-04-10
US20130116243A1 (en) 2013-05-09
EP2516435B1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
BR112012015677A2 (pt) Compostos farmacêuticos.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
WO2011033265A8 (en) Pharmaceutical compounds
CO6480975A2 (es) Mimetico de smac
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
MX2013008868A (es) Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
MX2014010560A (es) Composiciones farmaceuticas que comprenden metformina y un inhibidor de dpp-4 o un inhibidor de sglt-2.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
EA201390381A1 (ru) Триазиноксадиазолы
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX347241B (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
PH12016500092B1 (en) New azabenzimidazole derivatives

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO RJ860140134878 DE 11/08/2014 COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE JA FOI CONCEDIDO O EXAME PRIORITARIO DO PEDIDO DE PATENTE.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements